 | |
| Clinical data | |
|---|---|
| Trade names | Eumydrin |
| Other names | Methylatropinium; Methyl atropine; Methyl atropine nitrate; Methylatropine nitrate; Atropine methyl nitrate |
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C18H26NO3 |
| Molar mass | 304.410 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Methylatropine, sold under the brand nameEumydrin, is abelladonna derivative.[1]
In 1902, theBayer Company introduced methylatropine, a quaternary ammonium salt of atropine, as a mydriatic for dilation of the pupil during ophthalmic examination under the brand name of Eumydrin. Because of its highly polar nature it penetrated less readily into the central nervous system than did atropine; hence it was introduced for relieving pyloric spasm in infants.[2]
The blocking potency of methylatropine is approximately 10-20 times higher than that ofatropine at neuromuscular and ganglionic synapses.[3]
This article incorporatespublic domain material fromMethylatropine Bromide.National Institutes of Health. | Thisdrug article relating to thegastrointestinal system is astub. You can help Wikipedia byexpanding it. |
